The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy
Abstract
Antibodies targeting checkpoint inhibitors or co‐stimulatory receptors on T cells have shown significant antitumor efficacy in preclinical and clinical studies. In mouse tumor models, engagement of activating Fcγ receptor (FcγR)‐expressing immune cells was recently shown to be required for the tumoricidal activity of antibodies recognizing the tumor necrosis factor superfamily receptor (TNFR) GITR (CD357) and CTLA‐4 (CD152). In particular, activating FcγRs facilitated the selective elimination of intratumoral T‐cell populations. However, it remains unclear whether FcγRs contribute to the antitumor efficacy of other immunomodulatory antibodies. Here, we explored the mechanism of antitumor activity mediated by an agonistic antibody (clone OX86) to the co‐stimulatory TNFR OX40 (CD134). OX40 was highly expressed by intratumoral T cells, particularly those of the FoxP3+ regulatory T‐cell (Treg) lineage. OX86 administration resulted in the depletion of intratumoral regulatory T cells in an activating FcγR‐dependent manner, which correlated with tumor regression. Together with previous data from our group and others, these findings support a mechanism whereby antibodies targeting antigens highly expressed by intratumoral T cells can mediate their elimination by FcγR‐expressing immune cells, and facilitate subsequent antitumor immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Self-citationFcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
Fcγ Receptors: Old Friends and New Family Members
Nimmerjahn, F., & Ravetch, J. V. (2006) · Immunity · doi:10.1016/j.immuni.2005.11.010 · Cited by 1,072
Selby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., & Korman, A. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0013 · Cited by 857
Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells
Turk, M. J., Guevara-Patiño, J. A., Rizzuto, G. A., Engelhorn, M. E., & Houghton, A. N. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041130 · Cited by 540
Ox-40 Ligand: A Potent Costimulatory Molecule for Sustaining Primary CD4 T Cell Responses
Gramaglia, I., Weinberg, A. D., Lemon, M., & Croft, M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.12.6510 · Cited by 527
Ko, K., Yamazaki, S., Nakamura, K., Nishioka, T., Hirota, K., Yamaguchi, T., Shimizu, J., Nomura, T., Chiba, T., & Sakaguchi, S. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050940 · Cited by 466
Ko, K., Yamazaki, S., Nakamura, K., Nishioka, T., Hirota, K., Yamaguchi, T., Shimizu, J., Nomura, T., Chiba, T., & Sakaguchi, S. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.200509402092c · Cited by 462
Bulliard, Y., Jolicoeur, R., Windman, M., Rue, S. M., Ettenberg, S., Knee, D. A., Wilson, N. S., Dranoff, G., & Brogdon, J. L. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130573 · Cited by 446
Self-citationOX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
Piconese, S., Valzasina, B., & Colombo, M. P. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071341 · Cited by 405
Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity
Weinberg, A. D., Rivera, M.-M., Prell, R., Morris, A., Ramstad, T., Vetto, J. T., Urba, W. J., Alvord, G., Bunce, C., & Shields, J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.4.2160 · Cited by 387
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64859 · Cited by 386
Li, F., & Ravetch, J. V. (2011) · Science · doi:10.1126/science.1206954 · Cited by 335
Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40
Sugamura, K., Ishii, N., & Weinberg, A. D. (2004) · Nature Reviews Immunology · doi:10.1038/nri1371 · Cited by 335
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci73340 · Cited by 307
Kanamaru, F., Youngnak, P., Hashiguchi, M., Nishioka, T., Takahashi, T., Sakaguchi, S., Ishikawa, I., & Azuma, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.12.7306 · Cited by 285
Godfrey, W. R., Fagnoni, F. F., Harara, M. A., Buck, D., & Engleman, E. G. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.2.757 · Cited by 271
Wilson, N. S., Yang, B., Yang, A., Loeser, S., Marsters, S., Lawrence, D., Li, Y., Pitti, R., Totpal, K., Yee, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.012 · Cited by 248
Self-citationHirschhorn-Cymerman, D., Rizzuto, G. A., Merghoub, T., Cohen, A. D., Avogadri, F., Lesokhin, A. M., Weinberg, A. D., Wolchok, J. D., & Houghton, A. N. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082205 · Cited by 227
Quezada, S. A., Peggs, K. S., Simpson, T. R., Shen, Y., Littman, D. R., & Allison, J. P. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080099 · Cited by 218
Hirschhorn-Cymerman, D., Budhu, S., Kitano, S., Liu, C., Zhao, F., Zhong, H., Lesokhin, A. M., Avogadri-Connors, F., Yuan, J., Li, Y., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120532 · Cited by 159
Science gone translational: the OX40 agonist story
Weinberg, A. D., Morris, N. P., Kovacsovics-Bankowski, M., Urba, W. J., & Curti, B. D. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01069.x · Cited by 156
Signaling Through OX40 Enhances Antitumor Immunity
Jensen, S. M., Maston, L. D., Gough, M. J., Ruby, C. E., Redmond, W. L., Crittenden, M. R., Li, Y., Puri, S., Poehlein, C. H., Morris, N. P., et al. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.013 · Cited by 153
The Crystal Structure of the Costimulatory OX40-OX40L Complex
Compaan, D. M., & Hymowitz, S. G. (2006) · Structure · doi:10.1016/j.str.2006.06.015 · Cited by 150
Modulation of GITR for cancer immunotherapy
Schaer, D., Murphy, J. T., & Wolchok, J. D. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.011 · Cited by 147
Ronchetti, S., Nocentini, G., Bianchini, R., Krausz, L. T., Migliorati, G., & Riccardi, C. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.9.5916 · Cited by 100
Translating basic mechanisms of IgG effector activity into next generation cancer therapies.
Nimmerjahn, F., & Ravetch, J. V. (2012) · Europe PMC (PubMed Central) · Cited by 88
The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation
Blank, C. U. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000054 · Cited by 65
Fc-mOX40L Fusion Protein Produces Complete Remission and Enhanced Survival in 2 Murine Tumor Models
Sadun, R. E., Hsu, W.-E., Zhang, N., Nien, Y.-C., Bergfeld, S. A., Sabzevari, H., Lutsiak, M. E. C., Khawli, L. A., Hu, P., & Epstein, A. L. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31816a88e0 · Cited by 57
FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs
White, A. L., Chan, H. T. C., French, R. R., Beers, S. A., Cragg, M. S., Johnson, P., & Glennie, M. J. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1398-6 · Cited by 43
Fcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies
Kim, J. M., & Ashkenazi, A. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20131625 · Cited by 43
Ronchetti, S., Nocentini, G., Petrillo, M. G., & Riccardi, C. (2012) · The Scientific World JOURNAL · doi:10.1100/2012/308265 · Cited by 28
Cited by
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
Kim, J. M., & Chen, D. S. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw217 · Cited by 648
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.010 · Cited by 592
Resistance to PD1/PDL1 checkpoint inhibition
O'Donnell, J. S., Long, G. V., Scolyer, R. A., Teng, M. W. L., & Smyth, M. J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.007 · Cited by 572
Metadata
- Authors
- Bulliard, Y., Jolicoeur, R., Zhang, J., Dranoff, G., Wilson, N. S., & Brogdon, J. L.
- Venue
- Immunology & Cell Biology
- Publisher
- Wiley
- Published
- 2014-04-15
- Volume
- 92
- Issue
- 6
- Pages
- 475-480
- ISSN
- 0004-945X (ISSN-L)
- 0818-9641
- 1440-1711
- OpenAlex
- W2071875829
- Cited by
- 284
- References
- 34
- FWCI
- 13.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.